Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Inspections, Compliance, Enforcement, and Criminal Investigations

  • Print
  • Share
  • E-mail
-

McGuff Pharmaceuticals, Inc.- Close Out Letter 4/25/12

  

Department of Health and Human Services' logoDepartment of Health and Human Services

Public Health Service
Food and Drug Administration
 

Los Angeles District
Pacific Region
19701 Fairchild
Irvine, CA 92612M2506
Telephone: 949-608-2900
FAX: 949·608-4415

VIA UNITED PARCEL SERVICE
SIGNATURE REQUIRED

April 25, 2012

Mr. Ronald M. McGuff, President/CEO
McGuff Pharmaceuticals, Inc.
2921 W. MacArthur Blvd.
Suite 141
Santa Ana, CA 92704-6929

Dear Mr. McGuff:

The Food and Drug Administration has completed an evaluation of your written responses to the FDA 483, results of our inspection conducted August 15-24, 2011, and corrective actions to our Warning Letter [WL # 19-11], dated December 28, 2010. Based on our evaluation, it appears that you have addressed the violation(s) contained in the Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,

/S/

Alonza E. Cruse
District Director
Los Angeles District

-
-